The CD147 transmembrane glycoprotein is a hypothesized receptor for the SARS-CoV-2 virus. It has been observed that cancer patients, especially those with lung cancers, are very susceptible to developing COVID-19. However, the virus has been found to infect cancer cells that have low ACE2 expression. This suggests that alternative receptors may help facilitate viral entry into host cells. CD147 is known to be expressed at higher levels than ACE2 in both normal and cancerous tissue. Additionally, CD147 is a receptor for Cyclophilin A (CyPA) which causes pro-inflammatory leukocytes to migrate during a viral infection. There is currently no experimental evidence to support this hypothesis.